Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WHO Committee Wants Biosimilars Added To Pre-Qualification

Executive Summary

As biosimilars are added to the WHO’s list of essential drugs, an expert committee wants the global body to expand its pre-qualification program to cover more biosimilars.

You may also be interested in...



IGBA Makes Access Pact With WHO

The World Health Organization has taken an “important first step” towards increased collaboration with the generics and biosimilars industries through an agreement with the International Generic and Biosimilar Medicines Association to promote access to medicines.

IGBA Makes Access Pact With WHO

The WHO has taken an “important first step” towards increased collaboration with the generics and biosimilars industries through an agreement with the IGBA to promote access to medicines, including working towards a reduced trial burden for biosimilars and speeding up registration for both generics and biosimilars.

Pressure Mounts For German Tender Reforms

Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.

Topics

UsernamePublicRestriction

Register

GB140498

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel